• Philadelphia, PA (May 16, 2018) – Oncoceutics, Inc. announced today its support for legislation that will increase awareness for diffuse intrinsic pontine glioma (DIPG), the most devastating type of brain cancer in children. Oncoceutics supports the efforts of the Jack’s Angels Foundation and Rep. Stephen Knight (CA) to pass H.Res.69 to designate May 17th as “DIPG Awareness Day.” While numerous states already recognize May 17 as “DIPG Awareness Day,” this is the first national legislation dedicated exclusively to DIPG awareness.

    Oncoceutics is focusing its developmental work on brain tumors with a specific type of genetic mutation called H3 K27M that is present in many brain tumors and that occurs at a high rate (~80% of tumors) in DIPG. Emerging results from clinical trials with the company’s lead compound ONC201 in patients with H3 K27M-mutant glioma, including the first pediatric DIPG patient treated with ONC201, appear to be encouraging.

    Oncoceutics is currently enrolling patients in a clinical trial using ONC201 as a single agent or in combination with radiotherapy for patients with recurrent high-grade gliomas, including glioblastoma and DIPG. The trial (listed on clinicaltrials.gov as NCT03416530) is led by Sharon Gardner, MD, a pediatric neuro-oncologist at NYU Langone Health’s Stephen D. Hassenfeld Children’s Center for Cancer & Blood Disorders.

    See below for information on how you can support this initiative and refer to our website for more detailed information about ONC201 in midline gliomas and DIPG in addition to information on the company’s current clinical trials.


    House Res. 69 – Advocacy

    While House Res. 69 –the first national legislation dedicated exclusively to DIPG awareness– has been submitted to the Committee on Energy and Commerce and referred to the Subcommittee on Health, it must leave the committee before it can be voted on by the full House of Representatives.

    How to Take Action:

    1. Check if your representative is already a co-sponsor: https://www.govtrack.us/congress/bills/115/hres69/details

    2. Call to express your support and ask them to co-sponsor the resolution

    3. Use this sample letter to send either an email or snail mail

    4. Include this intro letter

    More information can be found on Jack’s Angels House Res. 69 Advocacy page


    About Oncoceutics

    Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds that selectively target G protein-coupled receptors for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers. The company recently completed a successful Phase I study in solid tumors and has begun additional Phase I/II and Phase II clinical programs in both solid and hematological malignancies. Oncoceutics and collaborative groups have received significant grants over the last two years, from institutions such as the National Cancer Institute, the U.S. Food and Drug Administration, the Pennsylvania Department of Health, and The Musella Foundation. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements and collaborations between Oncoceutics and leading cancer research institutions, including The University of Texas MD Anderson Cancer Center, the NIH/NCI, Harvard and the Fox Chase Cancer Center.  The company has established a robust intellectual property position, including several issued patents.

    Visit Oncoceutics or contact press@oncoceutics.com for more information.